5 research outputs found
Variance in mAO for each CAGexp allele (40â44 range) in normotensives and in pre-HD AHT patients.
<p>Numbers above the square brackets are the difference in median years between Pre-HD AHT and normotensives for each CAGexp allele.</p
Multiple regression analyses and descriptive statistics for mAO.
<p>Multiple regression analyses and descriptive statistics for mAO.</p
RT-qPCR analysis of <i>E2F2</i> gene expression in HD patients, according to <i>E2F2</i> rs2742976 genotype.
<p>Two methods were used. In Taqman assay, the expression of <i>E2F2</i> gene was analyzed in 31 samples (N <sub>TT</sub> = 4; N <sub>GT</sub> = 12, N <sub>GG</sub> = 15) with Hs00918089_m1 Taqman probe; the expression values were normalized respect to expression of <i>B2M</i> and <i>YWHAZ</i> reference genes. In SYBR Green assay, the <i>E2F2</i> gene expression was estimated in 31 samples (N<sub>TT</sub> = 5; N<sub>GT</sub> = 14, N<sub>GG</sub> = 12); the expression values were normalized to expression of <i>UBC</i> and <i>YWHAZ</i> reference genes. Results are expressed as fold over respective GG individuals. Asterisk denotes statistically significant differences (P<0.05) between GG and any other group, according to DataAssist software analysis (T-test) or REST software analysis (Pair Wise Reallocation Randomization test).</p
CAGexp and mAO comparisons between samples from Southern and Northern European populations.
<p>CAGexp and mAO comparisons between samples from Southern and Northern European populations.</p
CAGexp and eAO comparisons between samples from Southern and Northern European populations.
<p>CAGexp and eAO comparisons between samples from Southern and Northern European populations.</p